UNICA IRIS Institutional Research Information System

FARCI, PATRIZIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 66.826
NA - Nord America 5.768
AS - Asia 2.287
SA - Sud America 285
AF - Africa 45
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 4
Totale 75.222
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 62.500
US - Stati Uniti d'America 5.700
NL - Olanda 2.930
SG - Singapore 919
CN - Cina 883
UA - Ucraina 457
SE - Svezia 311
BR - Brasile 227
FI - Finlandia 165
VN - Vietnam 147
DE - Germania 139
GB - Regno Unito 139
FR - Francia 106
HK - Hong Kong 73
KR - Corea 56
IN - India 48
CA - Canada 32
BD - Bangladesh 30
AR - Argentina 21
IQ - Iraq 21
RU - Federazione Russa 18
JP - Giappone 14
IR - Iran 13
MX - Messico 13
EC - Ecuador 12
PK - Pakistan 12
ZA - Sudafrica 12
AT - Austria 10
ID - Indonesia 10
EG - Egitto 9
JM - Giamaica 9
UZ - Uzbekistan 9
MA - Marocco 8
PH - Filippine 8
PL - Polonia 8
LT - Lituania 7
VE - Venezuela 7
CL - Cile 6
IE - Irlanda 6
KZ - Kazakistan 6
TH - Thailandia 6
TR - Turchia 6
CO - Colombia 5
EU - Europa 4
GR - Grecia 4
KE - Kenya 4
RO - Romania 4
AU - Australia 3
AZ - Azerbaigian 3
CH - Svizzera 3
DK - Danimarca 3
ES - Italia 3
GE - Georgia 3
MY - Malesia 3
NI - Nicaragua 3
PA - Panama 3
SA - Arabia Saudita 3
UY - Uruguay 3
BE - Belgio 2
CG - Congo 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
KG - Kirghizistan 2
MU - Mauritius 2
NO - Norvegia 2
NP - Nepal 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
PY - Paraguay 2
SV - El Salvador 2
TN - Tunisia 2
AE - Emirati Arabi Uniti 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
BS - Bahamas 1
CY - Cipro 1
CZ - Repubblica Ceca 1
EE - Estonia 1
FJ - Figi 1
HN - Honduras 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
JO - Giordania 1
LB - Libano 1
LU - Lussemburgo 1
LV - Lettonia 1
NR - Nauru 1
PE - Perù 1
QA - Qatar 1
RS - Serbia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
ZW - Zimbabwe 1
Totale 75.222
Salva come PNG Salva come JPEG
Città #
Cagliari 61.520
Amsterdam 2.924
Uta 761
Fairfield 586
Singapore 494
Chandler 481
Woodbridge 450
Ashburn 408
Houston 369
San Jose 335
Boardman 256
Ann Arbor 249
Jacksonville 243
Seattle 236
Wilmington 230
Dallas 215
Cambridge 200
Nyköping 180
Beijing 162
Dearborn 123
Hefei 100
Santa Clara 90
Helsinki 88
Los Angeles 80
Nanjing 71
Boston 70
Lauterbourg 70
Buffalo 64
Hong Kong 63
Seoul 56
Shanghai 48
The Dalles 45
Ho Chi Minh City 40
Milan 40
Guangzhou 33
San Diego 32
Council Bluffs 31
Hanoi 30
New York 29
Shenyang 26
Hebei 22
Nanchang 22
Changsha 20
Verona 20
Chicago 18
Redwood City 18
São Paulo 18
Jiaxing 17
Sassari 17
London 15
Munich 14
Pune 14
Falls Church 13
Frankfurt am Main 13
Orem 13
Tianjin 13
Norwalk 12
Tokyo 12
Zhengzhou 12
Atlanta 11
Manchester 11
Brooklyn 10
Mountain View 10
Orange 10
Toronto 10
Auburn Hills 9
Guasila 9
Ningbo 9
Renton 9
Rio de Janeiro 9
Da Nang 8
Denver 8
Dong Ket 8
Phoenix 8
Baghdad 7
Haiphong 7
Jinan 7
Redmond 7
Redondo Beach 7
Tashkent 7
Warsaw 7
Washington 7
Belo Horizonte 6
Brasília 6
Chennai 6
Columbus 6
Dhaka 6
Kingston 6
Kunming 6
Rome 6
Turku 6
Vienna 6
Cairo 5
Dublin 5
Mexico City 5
Porto Alegre 5
Bangkok 4
Catania 4
Chongqing 4
Düsseldorf 4
Totale 72.122
Salva come PNG Salva come JPEG
Nome #
Evolution of hepatitis C viral quasispecies and hepatic injury in perinatally infected children followed prospectively 3.002
Liver Regeneration Signature in Hepatitis B Virus (HBV)-Associated Acute Liver Failure Identified by Gene Expression Profiling 2.978
Neutralizing antibodies to hepatitis C virus in perinatally infected children followed up prospectively 2.765
Profibrogenic chemokines and viral evolution predict rapid progression of hepatitis C to cirrhosis 2.693
Viral expression and molecular profiling in liver tissue versus microdissected hepatocytes in hepatitis B virus - associated hepatocellular carcinoma. 2.627
Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma 2.545
Association of chronic hepatitis C with recurrent brief depression 2.476
Integrated ordination of miRNA and mRNA expression profiles 2.357
Evaluation of antibodies to hepatitis C virus in a long-term prospective study of post-transfusion hepatitis among thalassemic children: comparison between first- and second- generation assay 2.250
Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue 2.208
Natural history of hepatitis C in thalassemia major: a long-term prospective study 2.157
Treatment of chronic hepatitis C in patients with glucose-6-phosphate dehydrogenase deficiency: is ribavirin harmful? 1.712
Epidemiology of infection with HIV-1 in Sardinia: a multicentre prospective study 1.711
Role of humoral immunity against hepatitis B virus core antigen in the pathogenesis of acute liver failure 1.701
Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma 1.695
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 1.644
null 1.610
Molecular signature and mechanisms of hepatitis D virus–associated hepatocellular carcinoma 1.516
Hepatic stem cells and transforming growth factor beta in hepatocellular carcinoma 1.469
null 1.445
Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: On-treatment kinetics of HBsAg serum levels vary by HBV genotype 1.444
Clinical Features of Hepatitis D 1.419
Specificity of an anti-capsid antibody associated with Hepatitis B Virus-related acute liver failure 1.373
New Insights into the HCV Quasispecies and Compartmentalization 1.356
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. 1.267
Experimental transmission of hepatitis C virus associated fulminant hepatitis to a chimpanzee 1.266
Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. 1.157
Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. 1.120
The use of molecular assays in the management of viral hepatitis 868
Comparing the safety, tolerability and quality of life in patients with chronic hepatitis B vs chronic hepatitis C treated with peginterferon alpha-2a. 823
Association of chronic hepatitis C with major depressive disorders: irrespective of interferon-alpha therapy 770
Viral escape and the failure of cellular immune responses 684
Treatment of chronic hepatitis D 652
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C 594
Treatment of patients with Chronic Hepatitis Delta 577
Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with peginterferon alfa-2a and ribavirin 558
Treatment of chronic hepatitis D: New advances, old challenges 551
Predicting response to peginterferon alfa-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B 546
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome 539
Chronic viral hepatitis D 536
In Vivo study of the HC-TN Strain of Hepatitis C Virus Recovered from a Case of Fulminant Hepatitis: RNA Transcripts of a Molecular Clone (pHC-TN) are Infectious in Chimpanzees but not in Huh7.5 cells 515
Natural history and experimental models of hepatitis C 501
The economics of treating chronic hepatitis C patients with peginterferon alpha-2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase 501
The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies 499
Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B 490
Hepatitis D (Delta) Virus 476
Immune Response to Hepatitis C Virus 470
Implicazioni biologiche e cliniche della quasispecie virale 467
Longitudinal analysis of serum chemokine levels in the course of HIV-1 infection 459
The quasispecies of hepatitis C virus and host immune response 452
Clinical relevance of hepatitis C virus genetic variability 447
A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures 444
Lack of protective immunity against reinfection with hepatitis C virus 444
L’epatite delta 441
Hepatitis C virus associated fulminant hepatic failure 416
Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. 407
Long term study of hepatitis C virus replication in non-A non-B hepatitis 405
null 399
Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassemic children 368
Prevention of hepatitis C virus infection in chimpanzee by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein 361
Milestones in Liver Disease 359
Delta hepatitis: an update 355
Acute viral hepatitis in Saudi Arabia: seroepidemiological analysis, risk factors, clinical manifestations, and evidence for a sixth hepatitis agent. 353
Virological mechanisms of viral persistence, resolution and reinfection 352
Hepatitis C virus. The importance of viral heterogeneity 350
Markers of hepatitis C virus infection in Sardinian blood donors: relationship with alanine aminotransferase levels. 350
The role of pre-core hepatitis B virus mutants on the long-term outcome of chronic hepatitis B virus hepatitis. A longitudinal study. 348
Peginterferon alfa-2a (40 KD) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels 344
Hepatitis type C after orthotopic liver transplantation: reinfection and disease recurrence. 333
Molecular basis of viral resistance to interferon in chronic hepatitis C 316
La ricerca biomedica 308
Prevention of hepatitis C virus infection in chimpanzee after antibody-mediated in vitro neutralization 308
HCV-associated lymphomas 307
HCV diversity, dynamics and turnover 300
Immunity elicited by hepatitis C virus. 295
Clinical significance of hepatitis C virus genotypes and quasispecies 291
Treatment of chronic hepatitis D with interferon alfa-2a 214
Long-term benefit of interferon alpha therapy of chronic hepatitis D: regression of advanced hepatic fibrosis 206
Totale 75.312
Salva come PNG Salva come JPEG
Categoria #
all - tutte 104.537
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 104.537
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021357 0 0 0 0 0 0 0 0 0 0 0 357
2021/20224.003 303 418 235 246 362 341 282 230 261 293 501 531
2022/20235.574 620 696 748 416 541 495 145 860 333 227 240 253
2023/20244.801 397 263 272 453 462 667 534 317 221 398 445 372
2024/20255.331 499 504 778 525 385 456 395 83 196 1.166 148 196
2025/20265.127 256 137 474 246 289 265 502 185 2.092 428 205 48
Totale 75.312